



coordinated care™

# Oncology Agents: Autologous Cellular Immunotherapy (Car-T) (Kymriah)

## WA.PHAR.91 Oncology Agents: Autologous Cellular Immunotherapy (Car-T) (Kymriah)

**Effective Date: January 1, 2018**

**Background:** Tisagenlecleucel (Kymriah™) is a CD19-directed, genetically modified, autologous T-cell immunotherapy agent managed and paid by the Health Care Authority for Medicaid members.

*All requests for authorization or payment must be referred to the Health Care Authority.*

### Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Code	Description
Q2042	TISAGENLECLEUCEL TO 600 M CAR-POS VI T CE PER TD

### History

Date	Action and Summary of Changes
06/24/2020	<ul style="list-style-type: none"> <li>New Policy Created</li> </ul>